These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 22544263

  • 1. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J, Zhou J, Zhao P, Wei J.
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [Abstract] [Full Text] [Related]

  • 2. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
    Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW.
    Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
    [Abstract] [Full Text] [Related]

  • 3. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P.
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 5. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [Abstract] [Full Text] [Related]

  • 6. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
    Mori S.
    Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC.
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [Abstract] [Full Text] [Related]

  • 8. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
    Laohapand C, Arromdee E, Tanwandee T.
    Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
    [Abstract] [Full Text] [Related]

  • 9. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH, Bae SC, Song GG.
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 12. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S.
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [Abstract] [Full Text] [Related]

  • 13. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.
    Wong GL, Wong VW, Yuen BW, Tse YK, Yip TC, Luk HW, Lui GC, Chan HL.
    J Hepatol; 2020 Jan; 72(1):57-66. PubMed ID: 31499132
    [Abstract] [Full Text] [Related]

  • 14. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T.
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [Abstract] [Full Text] [Related]

  • 15. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
    Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Takeda Y, Mimura N, Iseki T, Wu S, Arai M, Imazeki F, Saito K, Shirasawa H, Yokosuka O.
    Int J Mol Sci; 2014 Nov 21; 15(11):21455-67. PubMed ID: 25421241
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C, Furlini G, Andreone P.
    J Clin Virol; 2017 Aug 21; 93():66-70. PubMed ID: 28654775
    [Abstract] [Full Text] [Related]

  • 17. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Oct 21; 90(10):1219-23. PubMed ID: 21520001
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.
    Hung MH, Tien YC, Chiu YM.
    Adv Rheumatol; 2021 Apr 08; 61(1):22. PubMed ID: 33832541
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.